Clinical trial NCT04970238: Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction
Official title: Effect of Levosimendan on Left Ventricular Systolic Function and Heart Failure After PCI in Patients With Acute Anterior Myocardial Infarction-- Multicenter Prospective Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: PHASE4
Conditions: ST Elevation Myocardial Infarction
Heart Failure
Keywords: Heart Failure
Levosimendan
Lead sponsor: Shengjing Hospital
Sponsor class: OTHER
First posted: 2021-07-21
Enrollment: 500
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Reperfusion therapy for acute ST segment elevation myocardial infarction (STEMI) can significantly reduce mortality, but patients may still have heart failure and adverse cardiovascular events due to massive myocardial loss. About 20% of patients present with acute heart failure (AHF) at admission, It is the most important cause of hospital death in acute myocardial infarction. Because of the large necrotic area of acute anterior myocardial infarction, heart failure still occurs in a considerable number of patients even after revascularization (PCI). Myocardial protection of ischemic myocardium is a hot topic in clinical research.

Both ESC and Chinese heart failure guidelines recommend levosimendan for the treatment of acute decompensated heart failure. A large number of studies have proved that levosimendan can significantly reduce myocardial injury and improve cardiac function in patients with acute STEMI complicated with left ventricular dysfunction and cardiogenic shock compared with placebo. Basic research has confirmed that levosimendan can reduce the myocardial infarction area after acute coronary occlusion, improve the left ventricular function, and exert the effects of anti myocardial ischemia, myocardial injury, myocardial fibrosis, ventricular remodeling and anti apoptosis. However, there is still a lack of early preventive application of levosimendan in acute anterior myocardial infarction after PCI to improve ventricular remodeling and reduce the incidence of heart failure.

The purpose of this study was to investigate the effect of early prophylactic levosimendan on left ventricular remodeling, ischemic myocardial protection and the development of heart failure in patients with acute anterior myocardial infarction after PCI.


Eligibility criteria: Inclusion Criteria:

* 1. Age ≥ 18 years old.
* 2. Acute anterior wall myocardial infarction (ECG indicates acute anterior wall, acute anterior wall myocardial infarction, acute extensive anterior wall myocardial infarction).
* 3. The onset time of chest pain was less than 12 hours, and agreed to emergency PCI treatment.
* 4. Be able to understand and sign informed consent voluntarily.

Exclusion Criteria:

* 1. Patients who cannot undergo PCI treatment after coronary angiography, or those who fail to open blood vessels, or refuse to undergo PCI treatment.
* 2. Those whose coronary angiography results indicated myocardial infarction caused by non-coronary artery disease or residual stenosis \< 50% after reanalization of myocardial infarction without PCI treatment.
* 3. Patients with old anterior wall myocardial infarction.
* 4. Previous history of cardiac insufficiency.
* 5. Both anterior descending stent implantation, stent restenosis or stent thrombosis.
* 6. Symptomatic hypotension, systolic blood pressure \< 90mmHg (still \< 90mmHg with IABP)
* 7, body temperature \> 38.5℃, or with serious infectious diseases (severe myocarditis, severe pneumonia, severe urinary tract infection, etc.).
* 8. Severe other organ diseases (renal insufficiency: EGFR \< 30ml/min, severe liver insufficiency, moderate and severe anemia, malignant tumor, hematologic system diseases, etc.).
* 9. Known or suspected allergy to the active or inactive ingredients of the drug under study.
* 10. Participated in other drug clinical trials within 3 months before the trial.

Primary outcomes:
measure: Occurrence of heart failure
timeFrame: 6 month
measure: Major Adverse Cardiovascular Events (MACE)
timeFrame: 6 months
measure: Left ventricular systolic function
timeFrame: 72 hours
Secondary outcomes:
measure: NT-ProBNP
timeFrame: 30 days
measure: Patient quality of life score
timeFrame: 30 days
Other outcomes:
Locations:
city: Shenyang
country: China
facility: Shengjing Hospital
state: Liaoning
Study officials:
References: